A new study in the Journal of Clinical Oncology finds that a subset of pediatric ALL relapses may be triggered by the very chemotherapy which helped patients beat the cancer the first time.
ONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia.
ONCOLOGY discussed therapy options for adult acute lymphoblastic leukemia with Dr. Elias Jabbour, MD, Professor of Medicine in the Department of Leukemia at the MD Anderson Cancer Center in Houston, Texas.
A new study examined outcomes in infants with acute lymphoblastic leukemia treated with a lymphoid course of therapy vs a myeloid course.
A phase I study of a CAR T-cell therapy showed success in refining cell dosing and adverse event management protocols in patients with relapsed/refractory ALL.
Allogeneic transplantation was found not to improve overall outcome, in particular for patients who achieved MRD-negative status after induction.
Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.
Recent studies on CAR T-cell immunotherapy, and the recent approval of a new agent, add to evidence supporting the efficacy of these therapies.
T-ALL may be treatable by targeting signaling pathways affected by STIL-TAL1 fusion, according to a team from The Institute of Cancer Research, London, UK.
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.